Google today released its 2025 Year in Search list, but don’t mistake it for a ranking of the “top searches” or the “most searched” terms. This year’s recap focused on trending queries – the topics ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

More data is emerging supporting a sharp decline in the number of young adults identifying as transgender or non-binary. Last week, Fox News Digital reported on data shared by Eric Kaufman, a ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Understand what the interviewer is asking for by using test cases and questions about the problem. Established a set (2-3) of test cases to verify their own solution later. Established a set (1-2) of ...

Judge Amit P. Mehta said the company must hand over some of its search data to rivals, but did not force other big changes the U.S. wanted. By David McCabe David McCabe has covered the Google search ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...